InvestorsHub Logo
icon url

kabunushi

01/26/24 7:02 AM

#667228 RE: kabunushi #667220

Biosect, it goes without saying that I didn't mention about the payroll expenses Advent is carrying for your edification, obviously you are well aware of that expense factor - and of the fact that the staffing expenses will no doubt drop drastically per production run once Eden automation is in place. Just for now the fixed payroll costs account for most of the production cost.
icon url

dennisdave

01/26/24 7:03 AM

#667229 RE: kabunushi #667220

In the meantime, those staff can't be assigned to producing for other Advent customers

Advent disagrees with you

We operate the facility under a comprehensive IT infrastructure including EMS, eQMS eBMR and LIMS systems with secure storage for client documents and paperless systems. Our cleanroom suites are fully validated, with an in-house environmental monitoring system. Clients utilising our manufacturing service will benefit from ancillary services and technical support inclusive of process development, QC and validation. Ultra-cold and cryogenic facilities are available to external clients as off-site storage and are fully GMP compliant.



.
icon url

manibiotech

01/26/24 7:11 AM

#667234 RE: kabunushi #667220

Now that’s a very interesting take.
So “that staff” is being paid indirectly by NWBO because they can’t do anything else . So more or less all the operating expenses of Advent by that argument are being burdened by NWBO , then why is not Advent not a fully owned subsidiary of NWBO , so we can have the details of accounting on the financial reports ??
icon url

biosectinvestor

01/26/24 12:12 PM

#667368 RE: kabunushi #667220

Hi Kabunushi, my understanding and this also was the case way back when cell based companies did not have CDMO’s generally available, was that they have to be scaled and operational effectively to get a commercial license and you need the commercial license to get the marketing license. So nothing comes cheap, unfortunately. But by having the regional authority funding to develop Sawston, and the obligation to provide local manufacturing initially with excess capacity, you get potentially some subsidization and scaling early without only needing DCVax-L manufacturing. So the model NWBO/LP created here in my opinion was quite ingenious.